Trending...
- Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
- RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
- RAATV Premieres Original Reality Series "The Access Index: Jackson" June, 19
PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today presented details about the company's ongoing natural history study of adrenomyeloneuropathy (AMN) at the 8th Congress of the European Academy of Neurology (EAN) in Vienna. The intention of the CYGNET study is to assess disease progression in patients with AMN to inform the research and development of potential treatments, including SwanBio's lead candidate, SBT101, the first clinical-stage AAV-based gene therapy for AMN.
"At SwanBio, our approach to drug development begins with deepening our understanding of the origin and trajectory of diseases like AMN, ideally enabling us to deliver gene therapies that are both highly effective and meaningful for the quality of life of patients. With this in mind, our proprietary CYGNET study was designed to better characterize AMN disease progression, which varies from person to person," said Steven Zelenkofske, D.O., chief medical officer, SwanBio Therapeutics. "CYGNET is the first AMN clinical study to feature wearables, which may help us identify sensitive outcomes related to clinically relevant changes early in men with AMN."
SwanBio's CYGNET natural history study will track a number of variables over a two-year period, including:
More details about the CYGNET study, including demographics and disease characteristics of the first 21 patients enrolled, were presented during a virtual poster session at EAN.
More on The PennZone
SwanBio anticipates recruiting approximately 80 patients for the CYGNET natural history study; as of early June, the study was over 40% enrolled across five different global sites. Clinicians or patients interested in learning more about this study can review SwanBio's CYGNET flyer or contact SwanBio at clinicaltrials@swanbiotx.com.
Presentation Details
ePoster EPO-599: CYGNET: A prospective multicenter observational study of disease progression in patients with adrenomyeloneuropathy
Date & Time: June 27, 2022, 12:30 – 1:15 p.m. CEST
About SBT101
SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation. In preclinical studies, treatment with SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AMN mouse models. SBT101 was also shown to be well-tolerated in non-human primates at six months post-treatment. The clinical program for SBT101 builds on this positive preclinical data, plus the company's already deep understanding of the underlying pathophysiology of the disease and the patient experience of AMN.
SwanBio expects to initiate a randomized, controlled Phase 1/2 clinical trial designed to assess the safety and efficacy of SBT101 in patients with AMN in the second half of 2022. In early 2022, the FDA cleared SwanBio's Investigational New Drug application for SBT101 and granted SBT101 Fast Track and Orphan Drug Designation.
More on The PennZone
About Adrenomyeloneuropathy
Adrenomyeloneuropathy (AMN) is a progressive and debilitating neurodegenerative disease caused by mutations in the ABCD1 gene that disrupt the function of spinal cord cells and other tissues. AMN is characterized by loss of mobility in adulthood, incontinence, pain, and sexual dysfunction, which all affect quality of life. Between 8,000-10,000 men in the United States and European Union are living with AMN. There are no approved therapies for the treatment of the disease; current standard of care is limited to symptom management.
About SwanBio Therapeutics
SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions. SwanBio is advancing a pipeline of gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. SwanBio's lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN). SwanBio is supported by long-term, committed investment partners, including its primary investors Syncona, Ltd. (lead investor and majority shareholder) and Mass General Brigham Ventures. For more information, visit SwanBioTx.com.
References
Contacts
Media Contact:
Lara Furst
+1-703-946-0183
media@swanbiotx.com
Investor Contact:
Chelcie Lister
+1-910-777-3049
investors@swanbiotx.com
Patient and Physician Inquiries:
clinicaltrials@swanbiotx.com
"At SwanBio, our approach to drug development begins with deepening our understanding of the origin and trajectory of diseases like AMN, ideally enabling us to deliver gene therapies that are both highly effective and meaningful for the quality of life of patients. With this in mind, our proprietary CYGNET study was designed to better characterize AMN disease progression, which varies from person to person," said Steven Zelenkofske, D.O., chief medical officer, SwanBio Therapeutics. "CYGNET is the first AMN clinical study to feature wearables, which may help us identify sensitive outcomes related to clinically relevant changes early in men with AMN."
SwanBio's CYGNET natural history study will track a number of variables over a two-year period, including:
- Body sway, which has been shown to be an early predictor of disease progression and likelihood of falls in AMN, even in asymptomatic patients.1
- Both traditional motor tasks and novel activity and sleep outcomes, using wearable technology.
- Quality of life and several disease severity and functional impairment measures.
More details about the CYGNET study, including demographics and disease characteristics of the first 21 patients enrolled, were presented during a virtual poster session at EAN.
More on The PennZone
- MSBG Corporation Acquires GridWatch US Telemetry Automation System
- TAYP Expands Athlete Exposure Platform Beyond Georgia With New Push Into Virginia and the 757
- KT Medical Staffing Expands Concierge Nursing and Private Duty Nursing Services in Orange County
- The Millennium Alliance Achieves Great Place To Work® Certification™ Amid Continued Growth
- The Millennium Alliance Appoints Former Adweek Executive Eric Hayden Shakun as Chief Financial Officer to Accelerate Next Phase of Growth
SwanBio anticipates recruiting approximately 80 patients for the CYGNET natural history study; as of early June, the study was over 40% enrolled across five different global sites. Clinicians or patients interested in learning more about this study can review SwanBio's CYGNET flyer or contact SwanBio at clinicaltrials@swanbiotx.com.
Presentation Details
ePoster EPO-599: CYGNET: A prospective multicenter observational study of disease progression in patients with adrenomyeloneuropathy
Date & Time: June 27, 2022, 12:30 – 1:15 p.m. CEST
About SBT101
SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation. In preclinical studies, treatment with SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AMN mouse models. SBT101 was also shown to be well-tolerated in non-human primates at six months post-treatment. The clinical program for SBT101 builds on this positive preclinical data, plus the company's already deep understanding of the underlying pathophysiology of the disease and the patient experience of AMN.
SwanBio expects to initiate a randomized, controlled Phase 1/2 clinical trial designed to assess the safety and efficacy of SBT101 in patients with AMN in the second half of 2022. In early 2022, the FDA cleared SwanBio's Investigational New Drug application for SBT101 and granted SBT101 Fast Track and Orphan Drug Designation.
More on The PennZone
- T. Jones Group Named Finalist Across Multiple Categories at the 2026 Georgie Awards
- Circa 1825-1835 Columbia / Eagle flask sells for a record $177,840 in Glass Works Auctions' online auction held May 4th
- The Simplest Small Business You're Probably Not Thinking About
- San Francisco Writer Wins Webby Award, Internet's Highest Honor, for Website Based on her Novel
- EDC Weekend Comedy Special Featuring Don Barnhart & Friends — Use Promo Code FRIEND for 50% Off
About Adrenomyeloneuropathy
Adrenomyeloneuropathy (AMN) is a progressive and debilitating neurodegenerative disease caused by mutations in the ABCD1 gene that disrupt the function of spinal cord cells and other tissues. AMN is characterized by loss of mobility in adulthood, incontinence, pain, and sexual dysfunction, which all affect quality of life. Between 8,000-10,000 men in the United States and European Union are living with AMN. There are no approved therapies for the treatment of the disease; current standard of care is limited to symptom management.
About SwanBio Therapeutics
SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions. SwanBio is advancing a pipeline of gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. SwanBio's lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN). SwanBio is supported by long-term, committed investment partners, including its primary investors Syncona, Ltd. (lead investor and majority shareholder) and Mass General Brigham Ventures. For more information, visit SwanBioTx.com.
References
- van Ballegoij WJC, van de Stadt SIW, Huffnagel IC, Kemp S, van der Knaap MS, Engelen M. Postural Body Sway as Surrogate Outcome for Myelopathy in Adrenoleukodystrophy. Front Physiol. 2020;11:786.
Contacts
Media Contact:
Lara Furst
+1-703-946-0183
media@swanbiotx.com
Investor Contact:
Chelcie Lister
+1-910-777-3049
investors@swanbiotx.com
Patient and Physician Inquiries:
clinicaltrials@swanbiotx.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Mensa Foundation Event Reframes Brain Health for Every Age
- DLT Resolution, Inc. (Stock Symbol: DLTI) Expands Into the $224 Billion Life Settlements Market While Accelerating Telecom Growth Across Canada
- Pollock Begg Partner Joseph R. Williams Featured on 'CEOs You Should Know' Podcast
- Ashley Wineland's 'Love + Heartbreak' Tour Brings her Emotional and Empowering Album 'Wineland' to Nationwide Audiences
- People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
- With a Dream and a Team, Monalisa Okojie Is Empowering the Next Generation Through EXPOSE NGO
- Best Companies Group Launches Best Places to Work in PA Program
- American Properties Realty, Inc. Celebrates 2026 FAME Awards - Community of the Year - Heritage at South Brunswick
- Mel Blackwell to Keynote 2026 NSSF Marketing and Leadership Summit
- SmartCone and Samsung Launch RoadDefender™ to Enhance Real-Time Safety for Roadside Workers
- The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
- Kevin "Mr. Wonderful" O'Leary Begins New Universal Coin & Bullion Promotion of Gold and Silver
- Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
- HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
- PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey
- @tickerbitcoinbb and @girl_still_cute Announce the Arrival of SPROTO AEON BABY 1.0 – A New Chapter for the HarryPotterObamaSonic10Inu Universe
- Michigan Fitness Foundation Gifts EPEC Moves K–5 PE Curriculum Program to Educators during Michigan Moves Month
- Sidow Sobrino, the One and Only World's No.1 Superstar®, Launches Dangerous Joy
- Modern Site Builders Launches WolfResume.com, an AI Career Kit Built for ATS Hiring
- Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026